- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Glargine, LY2605541, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- Concord, California • Escondido, California • Fresno, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Gestational Diabetes, Pregnancy Related
- Interventions
- Insulin
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin degludec, insulin glargine, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 49 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec/liraglutide, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 44
- States / cities
- Muscle Shoals, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 37 more
- Conditions
- Diabetes, Surgery
- Interventions
- Lantus, Insulin
- Drug · Other
- Lead sponsor
- Tamra Dukatz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- Royal Oak, Michigan • Troy, Michigan
- Conditions
- Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
- Interventions
- Discharge Order Set (DOS), Enhanced Standard Care (ESC)
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Type1 Diabetes
- Interventions
- Glargine
- Biological
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 57
- States / cities
- Northridge, California • Palm Springs, California • Paramount, California + 53 more
- Conditions
- Type 1 Diabetes
- Interventions
- Lantus and short acting analogs Vs NPH and short acting analogs
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 6 Years to 25 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hyperglycemia, Leukemia
- Interventions
- insulin glargine recombinant, therapeutic insulin
- Biological · Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, Glimepiride, Insulin Glulisine, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Pregestational Diabetes, Pregnancy
- Interventions
- Use of insulin glargine once daily, Use of insulin glargine twice daily
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glulisine, Insulin Glargine, Premixed Insulin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 588 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 14
- States / cities
- Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 86
- States / cities
- Bay Minette, Alabama • Birmingham, Alabama • Huntsville, Alabama + 80 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- HM12460A
- Biological
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Prediabetes, Type 2 Diabetes
- Interventions
- Metformin, Glargine
- Drug
- Lead sponsor
- RISE Study Group
- Network
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 1 more
- Conditions
- Type 2 Diabetes
- Interventions
- Nateglinide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 28 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Type1 Diabetes Mellitus, Type2 Diabetes Mellitus
- Interventions
- HM12470
- Biological
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, Insulin Glulisine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 1 Diabetes
- Interventions
- MiniMed Paradigm REAL-Time System
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 7 Years to 70 Years
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 26
- States / cities
- La Jolla, California • Orange, California • Boulder, Colorado + 23 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Hyperglycemia, Diabetes Mellitus
- Interventions
- Lantus® (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey